Hypereosinophilia in patients with multiple sclerosis treated with natalizumab

Neurology

Volumn 77, Issue 16, 2011, Pages 1561-1564

  Abbas, M ^a   Lalive, P H ^a   Chofflon, M ^a   Simon, H U ^b   Chizzolini, C ^a   Ribi, C ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CORTICOSTEROID; ETIRACETAM; GLATIRAMER; IMMUNOGLOBULIN; METHYLPREDNISOLONE; NATALIZUMAB;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EOSINOPHIL; EOSINOPHIL COUNT; EPILEPSY; FEMALE; HUMAN; HYPEREOSINOPHILIA; LEUKOCYTE DIFFERENTIAL COUNT; MULTIPLE ORGAN FAILURE; MULTIPLE SCLEROSIS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PYRAMIDAL SIGN; SYSTEMIC THERAPY; TH1 CELL; TH2 CELL;

EID: 82955235691     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318233b391     Document Type: Article

References (14)

1. Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007;356:2622-2629. (Pubitemid 46961007)
2. Stüve O, Gold R, Chan A, Mix E, Zettl U, Kieseier BC. α4-Integrin antagonism with natalizumab: effects and adverse effects. J Neurol 2008;255(suppl 6):58-65.
3. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
4. André MC, Pacheco D, Antunes J, Silva R, Filipe P, Soares de Almeida LM. Generalized skin drug eruption to natalizumab in a patient with multiple sclerosis. Dermatol Online J 2010;16:14.
5. Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999;341:1112-1120. (Pubitemid 29466223)
6. Akdis CA, Akdis M, Simon D, et al. T cells and T cellderived cytokines as pathogenic factors in the nonallergic form of atopic dermatitis. J Invest Dermatol 1999;113: 628-634. (Pubitemid 29489628)
7. Simon HU, Plotz S, Simon D, et al. Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome. Eur J Immunol 2003;33:834-839. (Pubitemid 36546670)
8. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-1214. (Pubitemid 36359296)
9. Andina N, Didichenko S, Schmidt-Mende J, Dahinden CA, Simon HU. Proviral integration site for Moloney murine leukemia virus 1, but not phosphatidylinositol-3 kinase, is essential in the antiapoptotic signaling cascade initiated by IL-5 in eosinophils. J Allergy Clin Immunol 2009;123:603-611.
10. Florek J, Zephir H, Legrand F, et al. Hypereosinophilia under natalizumab in a French cohort of MS patients. Presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 15, 2010; Gothenberg, Sweden; P899.
11. Mittelbrunn M, Molina A, Escribese MM, et al. VLA-4 integrin concentrates at the peripheral supramolecular activation complex of the immune synapse and drives T helper 1 responses. Proc Natl Acad Sci USA 2004;101:11058-11063. (Pubitemid 38989583)
12. Zurawski G, de Vries JE. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 1994;15:19-26.
13. Vassina EM, Yousefi S, Simon D, Zwicky C, Conus S, Simon HU. cIAP-2 and survivin contribute to cytokinemediated delayed eosinophil apoptosis. Eur J Immunol 2006;36:1975-1984. (Pubitemid 44089062)
14. Zohren F, Toutzaris D, Klärner V, Hartung HP, Kieseier B, Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34 hematopoietic progenitor cells in humans. Blood 2008;111:3893-3895.